Skip to main content
SpringerLink
Log in

Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs—a Case Example of Erythropoietin

  • Brief/Technical Note
  • Published:
The AAPS Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Fried W. Erythropoietin and erythropoiesis. Exp Hematol. 2009;37(9):1007–15. https://doi.org/10.1016/j.exphem.2009.05.010.

    Article  CAS  PubMed  Google Scholar 

  2. Jelkmann W. Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant. 2009;24(5):1366–8. https://doi.org/10.1093/ndt/gfp058.

    Article  CAS  PubMed  Google Scholar 

  3. Storring PL, Gaines Das RE. The International Standard for Recombinant DNA-derived Erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J Endocrinol. 1992;134(3):459–84. https://doi.org/10.1677/joe.0.1340459.

    Article  CAS  PubMed  Google Scholar 

  4. Wognum A. Erythropoietin mini-review. https://www.stemcellcom/erythropoietin-lphtml. 2015.

  5. NIBSC. Third WHO International Standard for Erythropoietin, recombinant, for bioassay NIBSC code 11/170. 2012:version 1.0.

  6. NIBSC. WHO International Standard Erythropoietin, Human recombinant, NIBSC code 88/574. 2008:version 4.0.

  7. Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, et al. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther. 2007;81(6):873–9. https://doi.org/10.1038/sj.clpt.6100165.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol. 1996;80(1):140–8. https://doi.org/10.1152/jappl.1996.80.1.140.

    Article  CAS  PubMed  Google Scholar 

  9. Widness JA, Schmidt RL, Veng-Pedersen P, Modi NB, Sawyer ST. A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies. J Lab Clin Med. 1992;119(3):285–94.

    CAS  PubMed  Google Scholar 

  10. Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, et al. Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 2011;13(1):99–110. https://doi.org/10.1208/s12248-011-9251-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported in part by National Institutes of Health (NIH) US Public Health Service Program Project Grant P01 HL046925 and the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number U54TR001356.

Author information

Authors and Affiliations

  1. Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, S227 Phar, 115 S. Grand Ave., Iowa City, Iowa, 52242, USA

    Guohua An & Peter Veng-Pedersen

  2. Department of Pediatrics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, USA

    Robert L. Schmidt & John A. Widness

  3. Departments of Biochemistry and Molecular Biology and Pediatrics, University of Arkansas for Medical Sciences, Little Rock, USA

    Donald M. Mock

Authors
  1. Guohua An
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald M. Mock
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Veng-Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John A. Widness
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guohua An.

Ethics declarations

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

An, G., Schmidt, R.L., Mock, D.M. et al. Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs—a Case Example of Erythropoietin. AAPS J 21, 6 (2019). https://doi.org/10.1208/s12248-018-0269-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-018-0269-7

KEY WORDS

Search

Navigation